# OnCo record tovorafenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tovorafenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tovorafenib" ;
  schema:name "Tovorafenib"@en ;
  schema:description "Tovorafenib is a pill for the most common childhood brain tumour, low-grade glioma driven by BRAF changes, approved in 2024."@en ;
  schema:url <https://onco.cc/drugs/tovorafenib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tovorafenib-patients-relapsed-or-refractory-braf-altered-pediatric> ;
  onco:status "approved" ;
  onco:modality "Small-molecule type II RAF inhibitor" ;
  schema:alternateName "Ojemda" ;
  onco:approval "US 2024: Relapsed/refractory BRAF-altered paediatric low-grade glioma (accelerated)", "EU 2026: Relapsed/refractory paediatric low-grade glioma (conditional)" ;
  onco:acceleratedApproval "US 2024-04-23: Patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation." ;
  onco:related <https://onco.cc/biomarkers/braf-fusion/> ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:companies <https://onco.cc/companies/day-one-biopharmaceuticals/>, <https://onco.cc/companies/ipsen/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/nct05566795/> .